419571-32-7Relevant academic research and scientific papers
HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF
-
, (2017/04/01)
The present invention provides a compound having an mPGES-1 inhibitory activity and useful for the prophylaxis or treatment of pain, rheumatism, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arteriosclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and/or cancer including colorectal cancer. The present invention relates to a compound of formula [I-a], [I-b] or [I-c] or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the specification.
CCR5 antagonists: 3-(pyrrolidin-1-yl)propionic acid analogues with potent anti-HIV activity
Lynch, Christopher L.,Hale, Jeffrey J.,Budhu, Richard J.,Gentry, Amy L.,Finke, Paul E.,Caldwell, Charles G.,Mills, Sander G.,MacCoss, Malcolm,Shen, Dong-Ming,Chapman, Kevin T.,Malkowitz, Lorraine,Springer, Martin S.,Gould, Sandra L.,DeMartino, Julie A.,Siciliano, Salvatore J.,Cascierl, Margaret A.,Carella, Anthony,Carver, Gwen,Holmes, Karen,Schleif, William A.,Danzeisen, Renee,Hazuda, Daria,Kessler, Joseph,Lineberger, Janet,Miller, Michael,Emini, Emilio
, p. 2473 - 2475 (2007/10/03)
(Matrix presented) A novel approach to α,α-disubstituted-β -amino acids (β2,2-amino acids) was employed in the synthesis of a series of 3-(pyrrolidin-1-yl)-propionic acids possessing high affinity for the CCR5 receptor and potent anti-HIV activity. The rat pharmacokinetics for these new analogues featured higher bioavailabilities and lower rates of clearance as compared to cyclopentane 1.
